title: Predicting Biochemical Disease-Free Survival after Prostate Stereotactic Body Radiotherapy: Risk-Stratification and Patterns of Failure.
abstract: OBJECTIVE
  To determine appropriate risk-stratification factors for prostate cancer patients undergoing stereotactic body radiotherapy (SBRT).
  
  
  METHODS
  Between 2006 and 2010, 515 patients with organ-confined prostate cancer were treated with a regimen of five-fraction SBRT to dose of 35-36.25 Gy. By NCCN criteria, 324 patients were low risk, 153 were intermediate risk, and 38 were high risk. Patients were defined as unfavorable intermediate risk if Gleason 4 + 3 = 7 or >1 intermediate-risk factors (cT2b, c, PSA 10-20, Gleason 3 + 4 = 7). Cox regression analysis was used to determine risk factors significantly associated biochemical failure, and patterns of failure analyzed.
  
  
  RESULTS
  With median follow-up of 84 months, the 8-year disease-free survival was 93.6, 84.3, and 65.0% for low, intermediate, and high-risk group patients, respectively. Based on the above definition, 106 favorable intermediate-risk patients had excellent outcomes, with no significant difference compared to low-risk patients (7-year DFS 95.2 vs. 93.2%, respectively). The 47 unfavorable intermediate-risk patients had worse outcomes, similar to high-risk patients (7-year DFS 68.2 vs. 65.0%, respectively). Gleason score was the only significant factor associated with biochemical failure on multivariate analysis (p = 0.0003).
  
  
  CONCLUSIONS
  Patients with favorable intermediate-risk disease have excellent outcomes, comparable to low-risk patients. Patients with unfavorable intermediate-risk disease have significantly worse outcomes after SBRT, and should be considered for clinical trials or treatment intensification.
authors.affiliation: Flushing Radiation Oncology Services , New York, NY , USA.
authors.forename: Alan
authors.initials: A
authors.lastname: Katz
authors.affiliation: Department of Radiation Oncology, Weill Cornell Medical College , New York, NY , USA.
authors.forename: Silvia C
authors.initials: SC
authors.lastname: Formenti
authors.affiliation: Department of Radiation Oncology, Weill Cornell Medical College , New York, NY , USA.
authors.forename: Josephine
authors.initials: J
authors.lastname: Kang
keywords: Gleason score; prostate cancer; prostate-specific antigen; stereotactic body radiotherapy